Cellulose Derivatives Patents (Class 424/494)
-
Publication number: 20130344142Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.Type: ApplicationFiled: June 17, 2013Publication date: December 26, 2013Inventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara
-
Publication number: 20130309313Abstract: Disclosed are compositions including powdered green tea extract and a powdered preparation comprising polyunsaturated fatty acids. Also disclosed are methods of preparing the compositions and using the compositions in food products, as well as food products containing or that are prepared from the compositions.Type: ApplicationFiled: May 21, 2012Publication date: November 21, 2013Applicant: OCEAN NUTRITION CANADA LIMITEDInventors: Amber Lynn Gareau, Sharon Ann Spurvey Pittman, Lariza Beristain Taboada
-
Patent number: 8586094Abstract: Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.Type: GrantFiled: May 2, 2003Date of Patent: November 19, 2013Assignee: Jagotec AGInventors: Michael Vachon, Mishra K. Awadesh, Robert A. Snow, Pol-Henri Guivarc'H
-
Publication number: 20130302430Abstract: The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.Type: ApplicationFiled: July 17, 2013Publication date: November 14, 2013Inventors: Mahendra G. DEDHIYA, Suneel K. RASTOGI, Anil CHHETTRY, Narasimhan MANI, Niranjan RAO, Antonia PERICLOU
-
Patent number: 8580313Abstract: The present invention provides a pharmaceutical composition comprising taste-masked immediate release microcapsules which comprise fexofenadine and a water-insoluble polymer coating. These microcapsules and the pharmaceutical compositions comprising them have suitable drug content and desirable pharmaceutical properties, including a quick dissolution rate of fexofenadine combined with a taste masking effect.Type: GrantFiled: December 2, 2010Date of Patent: November 12, 2013Assignee: Aptalis Pharma LimitedInventors: Luigi Mapelli, Flavio Fabiani, Luigi Boltri, Paolo Gatti, Mauro Serratoni, Roberto Cassanmagnago
-
Publication number: 20130295188Abstract: The present disclosure relates to aqueous composition comprising hydroxypropyl methyl cellulose acetate succinate (HPMCAS) polymer dispersed in water, wherein the dispersed polymer is partially neutralized with at least one alkaline material. The instant disclosure also relates to compositions for use in methods of making capsule shells endowed with bulk enteric properties. The present disclosure also relates to capsules made according with the compositions and methods of the present disclosure.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Applicant: Capsugel France SASInventors: Dominique Nicolas CADE, Hugues Straub
-
Publication number: 20130295189Abstract: The invention relates to an improved method of manufacturing substantially spherical/ball-shaped tartaric acid starter pellets which are suitable for preparing active substance-containing medicament formulations, as well as the pellets as such that may be obtained in this way, and their use as starting material for the preparation of active substance-containing medicament formulations.Type: ApplicationFiled: July 10, 2013Publication date: November 7, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Johann-Georg MAIER
-
Publication number: 20130287847Abstract: The present invention relates to a solid molecular dispersion of fesoterodine hydrogen fumarate and a polymeric binder. The invention also relates to an inert core bead or particle which is coated with said solid molecular dispersion and to pharmaceutical formulations comprising such coated beads or particles.Type: ApplicationFiled: January 17, 2012Publication date: October 31, 2013Inventors: Roland Bodmeier, Alan Francis Carmody, Mesut Ciper, Anne Therese Gustaaf De Paepe, John Mark Heimlich, Martin Korber, Mathias Walther, Neil Feeder
-
Patent number: 8568784Abstract: Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications.Type: GrantFiled: November 10, 2010Date of Patent: October 29, 2013Assignee: Morehouse School of MedicineInventors: James W. Lillard, Rajesh Singh, Shailesh Singh
-
Patent number: 8568785Abstract: Provided is a process for producing spherical base granules comprising a easily water-soluble drug and suited for film coating by spraying a layering liquid over pharmaceutically inert spherical core particles, thereby coating the particles with a layer comprising the easily water-soluble drug, wherein (1) the spherical core particles have a microcrystalline cellulose content of 30 mass % or greater and a water absorbing capacity of 0.5 cm3/g or greater; and (2) the layering liquid is an aqueous solution comprising at least the easily water-soluble drug and a low water-soluble saccharide.Type: GrantFiled: July 18, 2007Date of Patent: October 29, 2013Assignee: Asahi Kasei Chemicals CorporationInventors: Yoshihito Yaginuma, Rika Matsumoto
-
Publication number: 20130266660Abstract: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.Type: ApplicationFiled: May 9, 2011Publication date: October 10, 2013Applicant: CIMA LABS Inc.Inventor: Ehab Hamed
-
Patent number: 8551501Abstract: The present invention relates to chitin microparticles and their medical uses, in particular in the treatment of allergy, or the treatment of conditions that would benefit from an upregulation of the cell mediated immune system, or an up-regulation of natural killer (NK) cell activity and/or the secretion of interferon-? (IFN-?).Type: GrantFiled: August 21, 2008Date of Patent: October 8, 2013Assignee: Mucovax Inc.Inventor: Peter Strong
-
Patent number: 8551526Abstract: A method for preparing poorly water soluble drug particles is disclosed. The method comprises dissolving a drug in at least one organic solvent to form a drug/organic mixture, spraying the drug/organic mixture into an aqueous solution and concurrently evaporating the organic solvent in the presence of the aqueous solution to form an aqueous dispersion of the drug particles. The resulting drug particles are in the nanometer to micrometer size range and show enhanced dissolution rates and reduced crystallinity when compared to the unprocessed drug. The present invention additionally contemplates products and processes for new drug formulations of insoluble drug particles having high dissolution rates and extremely high drug-to-excipient ratios.Type: GrantFiled: October 8, 2002Date of Patent: October 8, 2013Assignee: Board of Regents, The University of Texas SystemInventors: Keith P. Johnston, Robert O. Williams, III, Xiaoxia Chen
-
Publication number: 20130259941Abstract: Dosage forms having a core having a surface having means for controlling release(s) on an active agent(s); methods of manufacturing, tools used in manufacturing; and uses of the dosage forms are described.Type: ApplicationFiled: December 12, 2011Publication date: October 3, 2013Applicant: PURDUE PHARMA L.P.Inventor: Edward O'Donnell
-
Publication number: 20130259947Abstract: The present invention relates to an oral pharmaceutical composition comprising metronidazole, wherein metronidazole is released from the composition generally at the pH 5.0 and above.Type: ApplicationFiled: November 29, 2011Publication date: October 3, 2013Applicant: DR. REDDY'S LABORATORIES LTD.Inventors: Bijay Kumar Padhi, Muzammil Tariq, Sagar Dilip Mandawgade, Rajesh Gandhi, Rajeev Singh Raghuvanshi, Dushyanth Surakanti, Kent Allenby
-
Patent number: 8545892Abstract: Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product.Type: GrantFiled: June 26, 2009Date of Patent: October 1, 2013Assignee: Nano Pharmaceutical Laboratories, LLCInventor: Robert Niichel
-
Publication number: 20130243871Abstract: The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: NEOS THERAPEUTICS, LPInventors: Mark TENGLER, Russell McMAHEN
-
Publication number: 20130243870Abstract: The present invention provides a hydroxyalkyl cellulose having a viscosity of 1.10 mPa·s to 1.95 mPa·s in a 2%-concentration aqueous solution at 20° C., and a solid formulation containing the hydroxyalkyl cellulose.Type: ApplicationFiled: December 1, 2011Publication date: September 19, 2013Applicant: Nippon Soda Co., Ltd.Inventors: Satoru Abe, Takashi Kato
-
Publication number: 20130243869Abstract: The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: NEOS THERAPEUTICS, LPInventors: Mark TENGLER, Russell McMahen
-
Publication number: 20130243872Abstract: Provided is a pharmaceutical composite formulation for preventing or treating cardiovascular diseases, which comprises (1) a first particle comprising an HMG-CoA reductase inhibitor and a basic additive; and (2) a second particle comprising a core containing aspirin and an enteric coating layer coated on said core, wherein the difference in the average diameters of said first and second particles is 100 ?m to 800 ?m; a method for preparing same; and a method of validating the quality of same. The pharmaceutical composite formulation according to the present invention can improve the stability of an active ingredient and prevent adverse impacts between the active ingredients to thereby enable an accurate quality validation of the pharmaceutical composite formulation.Type: ApplicationFiled: December 14, 2011Publication date: September 19, 2013Applicant: HANMI SCIENCE CO., LTDInventors: Yong Il Kim, Young Jun Na, Jun Young Choi, Min Jung Kim, Jae Hyun Park, Jong Soo Woo
-
Publication number: 20130236554Abstract: The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.Type: ApplicationFiled: March 15, 2013Publication date: September 12, 2013Applicant: NEOS THERAPEUTICS, LPInventors: Mark TENGLER, Russell McMahen
-
Publication number: 20130236543Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.Type: ApplicationFiled: March 5, 2013Publication date: September 12, 2013Applicant: Boehringer Ingelheim International GmbHInventors: Masanori ITO, Kenji EGUSA, Kyle KLEINBECK, Roman MESSERSCHMID, Peter SCHNEIDER, Venkata VOLETI
-
Patent number: 8529955Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.Type: GrantFiled: November 21, 2011Date of Patent: September 10, 2013Assignee: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou, Gloria M. Gusler
-
Patent number: 8529954Abstract: The present invention relates to a granule of gamma-hydroxybutyric acid or of one of its pharmaceutically acceptable salts, characterized in that it comprises a solid core on which the gamma-hydroxybutyric acid or one of its salts is supported.Type: GrantFiled: November 10, 2009Date of Patent: September 10, 2013Assignee: Debregeas et Associes PharmaInventors: Christophe Lebon, Pascal Suplie
-
Publication number: 20130230596Abstract: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist.Type: ApplicationFiled: April 16, 2013Publication date: September 5, 2013Applicant: Elite Laboratories, Inc.Inventor: Atul M. Mehta
-
Patent number: 8524281Abstract: The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors.Type: GrantFiled: November 5, 2010Date of Patent: September 3, 2013Assignee: Wyeth LLCInventors: Sripriya Venkata Ramana Rao, Syed Muzafar Shah, Christopher Richard Diorio, Maja Vencl-Joncic, Eugene James Murphy
-
Publication number: 20130224290Abstract: The present invention relates to an oral pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core containing duloxetine, an optional separating layer, an enteric layer and an optional finishing layer.Type: ApplicationFiled: May 25, 2010Publication date: August 29, 2013Applicant: HETERO RESEARCH FOUNDATIONInventors: Bandi Parthasaradhi Reddy, Podili Khadgapathi, Sanikommu Venkata Ramana Reddy, Kalidindi Praveen Kumar
-
Patent number: 8518448Abstract: Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product.Type: GrantFiled: April 18, 2011Date of Patent: August 27, 2013Inventor: Robert Niichel
-
Publication number: 20130216617Abstract: The present invention relates to stable pharmaceutical compositions of (R)-lansoprazole or pharmaceutically acceptable salts thereof and process of preparing the same. The invention particularly provides pharmaceutical compositions of optically active (R)-isomer of lansoprazole with at least two functional coating layers.Type: ApplicationFiled: June 28, 2011Publication date: August 22, 2013Applicant: CADILA HEALTHCARE LIMITEDInventors: Sunilendu Bhushan Roy, Sushrut Krishnaji Kulkarni, Manohar Vishwanath Lalge, Vaibhav Panditrao Deshmukh
-
Publication number: 20130209567Abstract: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once—daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.Type: ApplicationFiled: August 9, 2012Publication date: August 15, 2013Applicant: Aptalis Pharamtech, Inc.Inventors: Gopi M. Venkatesh, James M. Clevenger
-
Publication number: 20130202688Abstract: The present invention relates to delayed release oral disintegrating pharmaceutical compositions of lansoprazole or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions.Type: ApplicationFiled: May 3, 2011Publication date: August 8, 2013Inventors: Sunilendu Bhushan Roy, Sushrut Krishnaji Kulkarni, Hemant Manilal Mamania
-
Publication number: 20130195986Abstract: Particles containing a tetracycline or one of its pharmaceutically acceptable salts and an antioxidant, formulations containing the same and their use in the treatment of infectious diseases are described. Methods of encapsulation of a tetracycline or one of its pharmaceutically acceptable salts and an antioxidant are also disclosed.Type: ApplicationFiled: May 12, 2011Publication date: August 1, 2013Applicant: HOVIONE INTER LTDInventors: William Heggie, Cristina Maria Sanches Simoes de Faria
-
Patent number: 8496969Abstract: The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient having an optional tastemasking coating, and a matrix comprising hydroxyalkylcellulose having a weight average molecular weight of from about 60,000 to about 5,000,000. The tablet possesses exceptionally good mouthfeel and stability.Type: GrantFiled: December 15, 2009Date of Patent: July 30, 2013Assignee: McNeil-PPC, Inc.Inventors: David Wynn, Nick Parikh
-
Publication number: 20130189360Abstract: An object of the present invention is to provide a compressed composition that is superior in terms of maintaining the function of a film or in terms of content uniformity even during tableting process. The present invention provides a compressed composition, comprising: coated granules containing a physiologically active compound or pharmacologically acceptable salt thereof, and an excipient, wherein the excipient contains at least one selected from the group consisting of low-substituted hydroxypropylcellulose, lactose and crystalline cellulose, and the total amount thereof is 0.5 parts by weight or more in 1 part by weight of the excipient, and the excipient is physically mixed with or coated onto the coated granules followed by compressing at low pressure.Type: ApplicationFiled: August 3, 2011Publication date: July 25, 2013Applicant: Eisai R&D Management Co., Ltd.Inventors: Hirokazu Sakamoto, Kentaro Nagane, Masami Nohara
-
Publication number: 20130177652Abstract: The invention relates to pharmaceutical oral dosage forms of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate (dabigatran etexilate) and the pharmacologically acceptable salts thereof, in particular dabigatran etexilate methanesulfonate.Type: ApplicationFiled: July 1, 2011Publication date: July 11, 2013Applicant: KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTOInventor: Vesna Kroselj
-
Publication number: 20130142880Abstract: The present invention refers to pharmaceutical beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and to their oral use in the treatment of inflammatory pathologies of the intestinal tract. Said compositions in microspheres comprise: a) a core consisting of a microsphere of inert material; b) a first intermediate coating comprising beclomethasone dipropionate and at least one physiologically acceptable excipient; c) a second modified-release gastro-resistant coating. The present invention also refers to a process for obtaining said compositions.Type: ApplicationFiled: August 2, 2011Publication date: June 6, 2013Applicant: SOFAR SPAInventor: Carla Labruzzo
-
Patent number: 8449920Abstract: Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product.Type: GrantFiled: April 8, 2011Date of Patent: May 28, 2013Inventor: Robert Niichel
-
Publication number: 20130129825Abstract: The invention relates to the use of an oral dosage form based on microgranules and/or microtablets to reduce the abusive use of at least one active principle contained therein. The aim of the invention is to prevent the diversion of an oral dosage form based on microgranules and/or microtablets containing at least one active principle capable of causing a dependency, a gelling agent, and a gelling activator. The gelling agent and the activator are only brought into contact with each other in the event of diversion by crushing. Said judiciously selected pair of excipients confers a viscosity to the formulation, such that said formulation cannot be administered by injection or does not release the active principle rapidly by forming a gel when it comes into contact with the mucous membrane if nasally administered.Type: ApplicationFiled: June 7, 2011Publication date: May 23, 2013Applicant: EthypharmInventor: Vincent Billoet
-
Publication number: 20130122101Abstract: A pharmaceutical composition may include a coated particulate which may include at least one active pharmaceutical ingredient, particularly one susceptible to abuse by an individual. The coated particles may include a fat/wax and have improved controlled release and/or crush resistance. Method of making these coated particulate and dosage forms therewith are also described.Type: ApplicationFiled: December 27, 2012Publication date: May 16, 2013Applicant: CIMA LABS INC.Inventor: CIMA LABS INC.
-
Publication number: 20130115298Abstract: The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with polymeric layer which enables the controlled release of the Venlafaxine Hydrochloride.Type: ApplicationFiled: November 21, 2011Publication date: May 9, 2013Applicant: LYCORED BIO LTD.Inventor: Yoram SELA
-
Publication number: 20130115286Abstract: Oral administration forms are described for the controlled release of an antibiotic selected from the group consisting of rifampicin, rifabutin, rifapentine, rifalazil and mixtures thereof, for treating bacterial infections of the gastrointestinal tract, in particular travellers' diarrhoea, hepatic encephalopathy, ulcerative colitis, irritable bowel syndrome (IBS), Crohn's disease, and IBD (inflammatory bowel disease) in general. Moreover, said oral administration forms allow reduction of the amounts of antibiotic to be taken, with respect to the known administration forms and without reaching blood concentrations such as to select resistant strains of tuberculosis mycobacteria.Type: ApplicationFiled: July 13, 2011Publication date: May 9, 2013Inventors: Mario Brufani, Bianca Maria Lagrasta, Rolando Marzella, Ilaria Medici, Silvio Silvestri
-
Patent number: 8435554Abstract: Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.Type: GrantFiled: December 30, 2008Date of Patent: May 7, 2013Assignee: Shin Nippon Biomedical Laboratories, Ltd.Inventors: Toshikazu Oki, Takashi Hanafusa, Shunji Haruta
-
Publication number: 20130108703Abstract: The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.Type: ApplicationFiled: April 25, 2012Publication date: May 2, 2013Applicant: Aptalis Pharmatech, Inc.Inventors: Gopi M. Venkatesh, Nehal H. Vyas, Michael Gosselin, Jin-Wang Lai
-
Patent number: 8420662Abstract: It is an object of the present invention to provide a stable solid preparation comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the present invention provides the stable solid preparation comprising the 4,5-epoxymorphinan derivative or the pharmacologically acceptable acid addition salt thereof as the effective ingredient, and comprising sodium thiosulfate, a sugar or a sugar alcohol and hydroxypropylcellulose having a low degree of substitution in an amount of 1 to 30% by weight per weight of a unit containing the effective ingredient.Type: GrantFiled: April 25, 2008Date of Patent: April 16, 2013Assignee: Toray Industries, Inc.Inventors: Suguru Takaki, Kotoe Ohta, Yasuhide Horiuchi, Masato Kobayashi, Junko Kawasaki, Eijiro Horisawa
-
Publication number: 20130084340Abstract: The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles.Type: ApplicationFiled: November 26, 2012Publication date: April 4, 2013Applicant: NEOS THERAPEUTICS, LPInventors: Mark Tengler, Paul Taskey, Daniel Lockhart, Russell McMahen
-
Publication number: 20130084332Abstract: This application relates to taste masked multi-layered particles an inert core, one or more coating layer(s) comprising a pharmaceutically active ingredient and a binder, an intermediate coating layer (seal coating) free from a low molecular weight water-soluble ionic compound and comprising a water-soluble pharmaceutical film-forming compound selected from (i) HPMC and PEG or (ii) PVP, and an outer coating layer (final or taste masking coating) free from a low molecular weight water-soluble ionic compound and comprising (i) a poly(meth)acrylate or (ii) a mixture comprising 60-90% (w/w) EC and 10-40% (w/w) HPMC, wherein the pharmaceutically active ingredient is water-soluble and comprises either at least one basic group and/or a bitter taste. Further disclosed are methods for the production of such particles and pharmaceutical compositions comprising them.Type: ApplicationFiled: August 13, 2012Publication date: April 4, 2013Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Martin FOLGER, Stefan LEHNER, Annette GRAVE, Norbert POELLINGER, Randolph Seidler
-
Patent number: 8409621Abstract: A method of forming particles, comprises accelerating a first stream comprising a first liquid, applying a charging voltage of at most 1.5 kV to the first stream, and vibrating the first stream, to form particles.Type: GrantFiled: November 13, 2007Date of Patent: April 2, 2013Assignee: The Board of Trustees of the University of IllinoisInventors: Kyekyoon Kim, Hyungsoo Choi, Young Bin Choy
-
Patent number: 8404281Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.Type: GrantFiled: June 8, 2010Date of Patent: March 26, 2013Assignee: Avant Garde Therapeutics & Technologies LLCInventors: Leo Rubin, Shaker Mousa
-
Publication number: 20130071481Abstract: The present invention relates to a coating particle containing a nuclear particle covered with a coating layer, and in the coating particle, the coating layer is a layer containing hydroxyalkyl cellulose and a binder.Type: ApplicationFiled: June 6, 2011Publication date: March 21, 2013Inventors: Hideki Ichikawa, Yoshinobu Fukumori, Satoru Abe, Yusuke Masue
-
Patent number: 8394415Abstract: A pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient having a shorter therapeutically effective plasma concentration duration, such as phenylephrine, and methods of administering the same are provided. This method provides improved therapeutic effect, in particular pain relief along with decongestant relief, over extended time periods.Type: GrantFiled: November 20, 2007Date of Patent: March 12, 2013Assignee: McNeil-PPC, IncInventors: Der-Yang Lee, Jen-Chi Chen, Vincent Chen, Robert Shen